Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.

Rhea-AI Summary

Progenity, Inc. (Nasdaq: PROG) will report its first quarter financial results on May 10, 2022, post-market close. The webcast and conference call will commence at 4:30 p.m. Eastern time. The company has recently completed its legal name change to Biora Therapeutics, which will officially be launched during the earnings call. The NASDAQ ticker will change from 'PROG' to 'BIOR' on the same day. Progenity specializes in gastrointestinal health and oral biotherapeutics, focusing on targeted drug delivery and diagnostic solutions.

Positive

• Company is transitioning to Biora Therapeutics, indicating a strategic rebranding.
• Launch of Biora Therapeutics brand coincides with the earnings call.

Negative

• None.

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30 p.m. Eastern time / 1:30 p.m. Pacific time that day to discuss the financial results and provide a corporate update.

As previously announced, Progenity is changing to Biora Therapeutics. Biora will focus on its pipeline of targeted and systemic oral biotherapeutics. The legal name change was completed on April 26, 2022, and the brand launch for Biora Therapeutics™ will coincide with the earnings call on May 10. The company’s NASDAQ ticker symbol will also change from “PROG” to “BIOR” on that day. No action is needed from current stockholders. The company’s common stock will continue to be listed on NASDAQ and the CUSIP will not change.

The live call on May 10 may be accessed by dialing 1-800-926-4402 (domestic) or 1-416-641-6700 (international) and entering the conference code: 22018599. A live webcast will be available via the Investor Relations section of the company website at bioratherapeutics.com, with a replay available online for 60 days following the call.

About Progenity
Progenity, Inc. is a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics and is developing a suite of investigational ingestible devices designed to provide precise drug delivery solutions and diagnostic sampling. Progenity will become Biora Therapeutics on May 10, 2022.

For more information visit www.progenity.com, or follow the company on LinkedIn or Twitter.

For updates about Biora Therapeutics, please follow on LinkedIn or Twitter.

Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
ir@progenity.com
(646) 627-8390

Media Contact
Kristin Schaeffer
CG Life
media@progenity.com  
(858) 457-2436

FAQ

When will Progenity report its first quarter financial results?

Progenity will report its first quarter financial results on May 10, 2022.

What is the new name of Progenity?

Progenity has changed its name to Biora Therapeutics.

What will be the new ticker symbol for Progenity?

The new ticker symbol for Progenity will be 'BIOR' starting May 10, 2022.

What time is the Progenity earnings call on May 10, 2022?

The earnings call will take place at 4:30 p.m. Eastern time on May 10, 2022.